PubMed:12439032 JSONTXT

{"project":"PennBioIE","denotations":[{"id":"T1","span":{"begin":71,"end":78},"obj":"protein"},{"id":"T2","span":{"begin":79,"end":92},"obj":"protein"},{"id":"T3","span":{"begin":98,"end":102},"obj":"protein"},{"id":"T4","span":{"begin":103,"end":116},"obj":"protein"},{"id":"T5","span":{"begin":151,"end":164},"obj":"protein"},{"id":"T6","span":{"begin":193,"end":197},"obj":"protein"},{"id":"T7","span":{"begin":236,"end":240},"obj":"protein"},{"id":"T8","span":{"begin":241,"end":254},"obj":"protein"},{"id":"T9","span":{"begin":428,"end":437},"obj":"protein"},{"id":"T10","span":{"begin":438,"end":442},"obj":"protein"},{"id":"T11","span":{"begin":501,"end":525},"obj":"protein"},{"id":"T12","span":{"begin":531,"end":538},"obj":"protein"},{"id":"T13","span":{"begin":539,"end":552},"obj":"protein"},{"id":"T14","span":{"begin":620,"end":627},"obj":"protein"},{"id":"T15","span":{"begin":628,"end":641},"obj":"protein"},{"id":"T16","span":{"begin":659,"end":663},"obj":"protein"},{"id":"T17","span":{"begin":664,"end":677},"obj":"protein"},{"id":"T18","span":{"begin":924,"end":928},"obj":"protein"},{"id":"T19","span":{"begin":929,"end":942},"obj":"protein"},{"id":"T20","span":{"begin":1065,"end":1069},"obj":"protein"},{"id":"T21","span":{"begin":1070,"end":1083},"obj":"protein"},{"id":"T22","span":{"begin":1232,"end":1239},"obj":"protein"},{"id":"T23","span":{"begin":1254,"end":1258},"obj":"protein"},{"id":"T24","span":{"begin":1259,"end":1272},"obj":"protein"},{"id":"T25","span":{"begin":1301,"end":1305},"obj":"protein"},{"id":"T26","span":{"begin":1306,"end":1319},"obj":"protein"},{"id":"T27","span":{"begin":1382,"end":1389},"obj":"protein"},{"id":"T28","span":{"begin":1404,"end":1408},"obj":"protein"},{"id":"T29","span":{"begin":1409,"end":1422},"obj":"protein"},{"id":"T30","span":{"begin":1451,"end":1455},"obj":"protein"},{"id":"T31","span":{"begin":1456,"end":1469},"obj":"protein"},{"id":"T32","span":{"begin":1526,"end":1533},"obj":"protein"},{"id":"T33","span":{"begin":1534,"end":1547},"obj":"protein"},{"id":"T34","span":{"begin":1577,"end":1581},"obj":"protein"},{"id":"T35","span":{"begin":1756,"end":1765},"obj":"protein"},{"id":"T36","span":{"begin":1837,"end":1841},"obj":"protein"},{"id":"T37","span":{"begin":1984,"end":1993},"obj":"protein"},{"id":"T38","span":{"begin":2080,"end":2084},"obj":"protein"},{"id":"T39","span":{"begin":2085,"end":2098},"obj":"protein"},{"id":"T40","span":{"begin":2218,"end":2222},"obj":"protein"},{"id":"T41","span":{"begin":2223,"end":2236},"obj":"protein"},{"id":"T42","span":{"begin":2385,"end":2392},"obj":"protein"},{"id":"T43","span":{"begin":2407,"end":2411},"obj":"protein"},{"id":"T44","span":{"begin":2412,"end":2425},"obj":"protein"},{"id":"T45","span":{"begin":2454,"end":2458},"obj":"protein"},{"id":"T46","span":{"begin":2459,"end":2472},"obj":"protein"},{"id":"T47","span":{"begin":2534,"end":2541},"obj":"protein"},{"id":"T48","span":{"begin":2556,"end":2560},"obj":"protein"},{"id":"T49","span":{"begin":2561,"end":2574},"obj":"protein"},{"id":"T50","span":{"begin":2603,"end":2607},"obj":"protein"},{"id":"T51","span":{"begin":2608,"end":2621},"obj":"protein"},{"id":"T52","span":{"begin":2742,"end":2746},"obj":"protein"},{"id":"T53","span":{"begin":2747,"end":2756},"obj":"protein"},{"id":"T54","span":{"begin":2936,"end":2940},"obj":"protein"},{"id":"T55","span":{"begin":2941,"end":2950},"obj":"protein"},{"id":"T56","span":{"begin":3003,"end":3007},"obj":"protein"},{"id":"T57","span":{"begin":3008,"end":3021},"obj":"protein"},{"id":"T58","span":{"begin":3100,"end":3104},"obj":"protein"},{"id":"T59","span":{"begin":3105,"end":3118},"obj":"protein"},{"id":"T60","span":{"begin":3146,"end":3159},"obj":"protein"}],"text":"Intensified chemotherapy increases the survival rates in patients with stage 4 neuroblastoma with MYCN amplification.\nPURPOSE: Patients with high-risk neuroblastoma who have multiple copies of MYCN fare much worse than do those without MYCN amplification; however, it has not been clarified whether intensified chemotherapy with or without blood stem cell transplantation can alter the extremely poor prognosis of patients with amplified MYCN.\nMETHODS AND RESULTS: Between 1985 and 1999, 301 patients older than age 12 months with stage 4 neuroblastoma were treated. From January 1985 to February 1991, 80 patients with stage 4 neuroblastoma with and without MYCN amplification uniformly received induction chemotherapy with regimen A(1) (cyclophosphamide 1,200 mg/m(2) and vincristine 1.5 mg/m(2) on day 1, tetra-hydropyranyl [THP]-Adriamycin 40 mg/m(2) on day 3, and cisplatin 90 mg/m(2) on day 5). Among 22 patients with MYCN amplification, nine (40.9%) achieved a complete remission and seven (31.8%) underwent stem cell transplantation. Of 58 patients without MYCN amplification, 43 (74.1%) achieved a complete remission and 14 (24.1%) underwent stem cell transplantation. The 5-year relapse-free survival rates were 23.2% for stage 4 patients with MYCN amplification and 33.3% for those without MYCN amplification (P = 0.029); the 5-year overall survival rates were 32.8% for stage 4 patients with MYCN amplification and 42.8% for those without MYCN amplification (P \u003e 0.05). From March 1991 to June 1998, patients with stage 4 neuroblastoma who had 10 or more copies of MYCN were treated with regimen A(3) (cyclophosphamide 1,200 mg/m(2) per day on days 1 and 2, THP-Adriamycin 40 mg/m(2) on day 3, etoposide 100 mg/m(2) per day on days 1 to 5, and cisplatin 25 mg/m(2) per day on days 1 to 5); those with fewer than 10 copies of MYCN received regimen new A (cyclophosphamide 1,200 mg/m on day 1, THP-Adriamycin 40 mg/m on day 3, etoposide 100 mg/m per day on days 1 to 5, and cisplatin 90 mg/m on day 5), which is similar in intensity to regimen A. Among 88 patients with MYCN amplification, 63 (71.6%) achieved a complete remission and 63 (71.68%) underwent stem cell transplantation. Of 133 patients without MYCN amplification, 93 (69.9%) achieved a complete remission and 71 (53.4%) underwent stem cell transplantation. The 5-year relapse-free survival rates were 36.0% for stage 4 patients with MYCN amplification and 32.2% for those without MYCN amplification (P \u003e 0.05), the 5-year overall survival rates were 34.0% for stage 4 patients with MYCN amplification and 38.9% for those without MYCN amplification (P \u003e 0.05). The difference in relapse-free survival rates was significantly different (P = 0.003) between patients with MYCN-amplified tumor treated before (regimen A(1)) versus after 1991 (regimen A(3)).\nCONCLUSIONS: With the use of the more intensive induction regimen A plus blood stem cell transplantation for MYCN-amplified patients, survival curves for those with or without MYCN amplification now appear similar. Higher doses of chemotherapy may ameliorate the effect of MYCN amplification in patients with high-risk neuroblastoma."}

{"project":"DisGeNET5_gene_disease","denotations":[{"id":"12439032-13#58#62#gene4613","span":{"begin":3100,"end":3104},"obj":"gene4613"},{"id":"12439032-13#104#117#diseaseC0027819","span":{"begin":3146,"end":3159},"obj":"diseaseC0027819"}],"relations":[{"id":"58#62#gene4613104#117#diseaseC0027819","pred":"associated_with","subj":"12439032-13#58#62#gene4613","obj":"12439032-13#104#117#diseaseC0027819"}],"text":"Intensified chemotherapy increases the survival rates in patients with stage 4 neuroblastoma with MYCN amplification.\nPURPOSE: Patients with high-risk neuroblastoma who have multiple copies of MYCN fare much worse than do those without MYCN amplification; however, it has not been clarified whether intensified chemotherapy with or without blood stem cell transplantation can alter the extremely poor prognosis of patients with amplified MYCN.\nMETHODS AND RESULTS: Between 1985 and 1999, 301 patients older than age 12 months with stage 4 neuroblastoma were treated. From January 1985 to February 1991, 80 patients with stage 4 neuroblastoma with and without MYCN amplification uniformly received induction chemotherapy with regimen A(1) (cyclophosphamide 1,200 mg/m(2) and vincristine 1.5 mg/m(2) on day 1, tetra-hydropyranyl [THP]-Adriamycin 40 mg/m(2) on day 3, and cisplatin 90 mg/m(2) on day 5). Among 22 patients with MYCN amplification, nine (40.9%) achieved a complete remission and seven (31.8%) underwent stem cell transplantation. Of 58 patients without MYCN amplification, 43 (74.1%) achieved a complete remission and 14 (24.1%) underwent stem cell transplantation. The 5-year relapse-free survival rates were 23.2% for stage 4 patients with MYCN amplification and 33.3% for those without MYCN amplification (P = 0.029); the 5-year overall survival rates were 32.8% for stage 4 patients with MYCN amplification and 42.8% for those without MYCN amplification (P \u003e 0.05). From March 1991 to June 1998, patients with stage 4 neuroblastoma who had 10 or more copies of MYCN were treated with regimen A(3) (cyclophosphamide 1,200 mg/m(2) per day on days 1 and 2, THP-Adriamycin 40 mg/m(2) on day 3, etoposide 100 mg/m(2) per day on days 1 to 5, and cisplatin 25 mg/m(2) per day on days 1 to 5); those with fewer than 10 copies of MYCN received regimen new A (cyclophosphamide 1,200 mg/m on day 1, THP-Adriamycin 40 mg/m on day 3, etoposide 100 mg/m per day on days 1 to 5, and cisplatin 90 mg/m on day 5), which is similar in intensity to regimen A. Among 88 patients with MYCN amplification, 63 (71.6%) achieved a complete remission and 63 (71.68%) underwent stem cell transplantation. Of 133 patients without MYCN amplification, 93 (69.9%) achieved a complete remission and 71 (53.4%) underwent stem cell transplantation. The 5-year relapse-free survival rates were 36.0% for stage 4 patients with MYCN amplification and 32.2% for those without MYCN amplification (P \u003e 0.05), the 5-year overall survival rates were 34.0% for stage 4 patients with MYCN amplification and 38.9% for those without MYCN amplification (P \u003e 0.05). The difference in relapse-free survival rates was significantly different (P = 0.003) between patients with MYCN-amplified tumor treated before (regimen A(1)) versus after 1991 (regimen A(3)).\nCONCLUSIONS: With the use of the more intensive induction regimen A plus blood stem cell transplantation for MYCN-amplified patients, survival curves for those with or without MYCN amplification now appear similar. Higher doses of chemotherapy may ameliorate the effect of MYCN amplification in patients with high-risk neuroblastoma."}

{"project":"DisGeNET","denotations":[{"id":"T0","span":{"begin":3100,"end":3104},"obj":"gene:4613"},{"id":"T1","span":{"begin":3146,"end":3159},"obj":"disease:C0027819"},{"id":"T2","span":{"begin":3100,"end":3104},"obj":"gene:4613"},{"id":"T3","span":{"begin":3146,"end":3159},"obj":"disease:C0700095"}],"relations":[{"id":"R1","pred":"associated_with","subj":"T0","obj":"T1"},{"id":"R2","pred":"associated_with","subj":"T2","obj":"T3"}],"namespaces":[{"prefix":"gene","uri":"http://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"disease","uri":"http://purl.bioontology.org/ontology/MEDLINEPLUS/"}],"text":"Intensified chemotherapy increases the survival rates in patients with stage 4 neuroblastoma with MYCN amplification.\nPURPOSE: Patients with high-risk neuroblastoma who have multiple copies of MYCN fare much worse than do those without MYCN amplification; however, it has not been clarified whether intensified chemotherapy with or without blood stem cell transplantation can alter the extremely poor prognosis of patients with amplified MYCN.\nMETHODS AND RESULTS: Between 1985 and 1999, 301 patients older than age 12 months with stage 4 neuroblastoma were treated. From January 1985 to February 1991, 80 patients with stage 4 neuroblastoma with and without MYCN amplification uniformly received induction chemotherapy with regimen A(1) (cyclophosphamide 1,200 mg/m(2) and vincristine 1.5 mg/m(2) on day 1, tetra-hydropyranyl [THP]-Adriamycin 40 mg/m(2) on day 3, and cisplatin 90 mg/m(2) on day 5). Among 22 patients with MYCN amplification, nine (40.9%) achieved a complete remission and seven (31.8%) underwent stem cell transplantation. Of 58 patients without MYCN amplification, 43 (74.1%) achieved a complete remission and 14 (24.1%) underwent stem cell transplantation. The 5-year relapse-free survival rates were 23.2% for stage 4 patients with MYCN amplification and 33.3% for those without MYCN amplification (P = 0.029); the 5-year overall survival rates were 32.8% for stage 4 patients with MYCN amplification and 42.8% for those without MYCN amplification (P \u003e 0.05). From March 1991 to June 1998, patients with stage 4 neuroblastoma who had 10 or more copies of MYCN were treated with regimen A(3) (cyclophosphamide 1,200 mg/m(2) per day on days 1 and 2, THP-Adriamycin 40 mg/m(2) on day 3, etoposide 100 mg/m(2) per day on days 1 to 5, and cisplatin 25 mg/m(2) per day on days 1 to 5); those with fewer than 10 copies of MYCN received regimen new A (cyclophosphamide 1,200 mg/m on day 1, THP-Adriamycin 40 mg/m on day 3, etoposide 100 mg/m per day on days 1 to 5, and cisplatin 90 mg/m on day 5), which is similar in intensity to regimen A. Among 88 patients with MYCN amplification, 63 (71.6%) achieved a complete remission and 63 (71.68%) underwent stem cell transplantation. Of 133 patients without MYCN amplification, 93 (69.9%) achieved a complete remission and 71 (53.4%) underwent stem cell transplantation. The 5-year relapse-free survival rates were 36.0% for stage 4 patients with MYCN amplification and 32.2% for those without MYCN amplification (P \u003e 0.05), the 5-year overall survival rates were 34.0% for stage 4 patients with MYCN amplification and 38.9% for those without MYCN amplification (P \u003e 0.05). The difference in relapse-free survival rates was significantly different (P = 0.003) between patients with MYCN-amplified tumor treated before (regimen A(1)) versus after 1991 (regimen A(3)).\nCONCLUSIONS: With the use of the more intensive induction regimen A plus blood stem cell transplantation for MYCN-amplified patients, survival curves for those with or without MYCN amplification now appear similar. Higher doses of chemotherapy may ameliorate the effect of MYCN amplification in patients with high-risk neuroblastoma."}